bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Figure 3 from Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models
Authors: Logsdon Derek P. , Grimard Michelle , Luo Meihua , Shahda Safi , Jiang Yanlin , Tong Yan , Yu Zhangsheng , Zyromski Nicholas , Schipani Ernestina , Carta Fabrizio , Supuran Claudiu T. , Korc Murray , Ivan Mircea , Kelley Mark R. , Fishel Melissa L.
Published: April 2023

APE1/Ref-1 interactions with STAT3 and NFκB are stimulated by IL-6 and TNFα (respectively) under normoxic conditions
Supplementary Table S4 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Authors: Weiss Andreas , Adler Flavia , Buhles Alexandra , Stamm Christelle , Fairhurst Robin A. , Kiffe Michael , Sterker Dario , Centeleghe Mario , Wartmann Markus , Kinyamu-Akunda Jacqueline , Schadt Heiko S. , Couttet Philippe , Wolf Armin , Wang Youzhen , Barzaghi-Rinaudo Patrizia , Murakami Masato , Kauffmann Audrey , Knoepfel Thomas , Buschmann Nicole , Leblanc Catherine , Mah Robert , Furet Pascal , Blank Jutta , Hofmann Francesco , Sellers William R. , Graus Porta Diana
Published: April 2023

Activity of FGF401 in PDXs
Supplementary Table S2 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Authors: Weiss Andreas , Adler Flavia , Buhles Alexandra , Stamm Christelle , Fairhurst Robin A. , Kiffe Michael , Sterker Dario , Centeleghe Mario , Wartmann Markus , Kinyamu-Akunda Jacqueline , Schadt Heiko S. , Couttet Philippe , Wolf Armin , Wang Youzhen , Barzaghi-Rinaudo Patrizia , Murakami Masato , Kauffmann Audrey , Knoepfel Thomas , Buschmann Nicole , Leblanc Catherine , Mah Robert , Furet Pascal , Blank Jutta , Hofmann Francesco , Sellers William R. , Graus Porta Diana
Published: April 2023

Pharmacologic profiling of FGF401 in cancer cell lines
Supplementary Figures 1 through 4 and Supplementary Materials and Methods from Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations
Authors: Larrue Clément , Saland Estelle , Vergez François , Serhan Nizar , Delabesse Eric , Mansat-De Mas Véronique , Hospital Marie-Anne , Tamburini Jérôme , Manenti Stéphane , Sarry Jean Emmanuel , Récher Christian
Published: April 2023

This file contains additional figures that enrich results presented in the main manuscript. We evaluated the impact of the 2-DG on the expression of both wild-type FLT3 and KIT. Then, we excluded a potential role for cellular protein degradation pathways such as apoptosis or ubiquitin-proteasome pathway in response to 2-DG. We also investigated the subcellular location of FLT3 after 2-DG treatment. In addition, we assessed the impact of the 2-DG on the phosphorylation of Lyn and Akt, Finally, this file contains data on the effects of 2-DG in a rare primary sample patient carrying the FLT3-TKD mutation. Supplementary material and methods for qRT-PCR.
Fig. S3 from Nuclear PTEN Localization Contributes to DNA Damage Response in Endometrial Adenocarcinoma and Could Have a Diagnostic Benefit for Therapeutic Management of the Disease
Authors: Mukherjee Ananda , Patterson Amanda L. , George Jitu W. , Carpenter Tyler J. , Madaj Zachary B. , Hostetter Galen , Risinger John I. , Teixeira Jose M.
Published: April 2023

Supplementary Figure 3. PTEN localization in cytoplasm and nuclei of epithelial cells in ANT and EndoCA by grade. PTEN immunostaining was performed on adjacent normal tissues (ANT) and matched primary endometrial tumors (EndoCA). Quantification of staining intensities was assessed by histo-scoring (H-score) in cytoplasm and nuclei of epithelial cells. Average intensities are expressed as median with 95% CI, and statistical significance are determined by Wilcoxon matched-pairs signed rank test. A, n=10 matched ANT and Grade1 tumors. B, n=9 matched ANT and Grade 2 tumors. C, n=10 matched ANT and Grade 3 tumors.
FGF401 characterizing data from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Authors: Weiss Andreas , Adler Flavia , Buhles Alexandra , Stamm Christelle , Fairhurst Robin A. , Kiffe Michael , Sterker Dario , Centeleghe Mario , Wartmann Markus , Kinyamu-Akunda Jacqueline , Schadt Heiko S. , Couttet Philippe , Wolf Armin , Wang Youzhen , Barzaghi-Rinaudo Patrizia , Murakami Masato , Kauffmann Audrey , Knoepfel Thomas , Buschmann Nicole , Leblanc Catherine , Mah Robert , Furet Pascal , Blank Jutta , Hofmann Francesco , Sellers William R. , Graus Porta Diana
Published: April 2023

This file provides the full characterization of FGF401
Supplemental Figure 5 from Fenretinide, Tocilizumab, and Reparixin Provide Multifaceted Disruption of Oral Squamous Cell Carcinoma Stem Cell Properties: Implications for Tertiary Chemoprevention
Authors: Mallery Susan R. , Wang Daren , Santiago Brian , Pei Ping , Bissonnette Caroline , Jayawardena Jayanetti Asiri , Schwendeman Steven P. , Spinney Richard , Lang James
Published: April 2023

Selective siRNA silencing reduces YAP and TAZ protein levels
Supplemental Figure 4 from Fenretinide, Tocilizumab, and Reparixin Provide Multifaceted Disruption of Oral Squamous Cell Carcinoma Stem Cell Properties: Implications for Tertiary Chemoprevention
Authors: Mallery Susan R. , Wang Daren , Santiago Brian , Pei Ping , Bissonnette Caroline , Jayawardena Jayanetti Asiri , Schwendeman Steven P. , Spinney Richard , Lang James
Published: April 2023

Levels of YAP-TAZ nuclear translocations are comparable between stem selected and parent cells
Supplementary Figure S7 from Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma
Authors: Elbanna May , Orillion Ashley R. , Damayanti Nur P. , Adelaiye-Ogala Remi , Shen Li , Miles Kiersten Marie , Chintala Sreenivasulu , Ciamporcero Eric , Ramakrishnan Swathi , Ku Sheng-yu , Rex Karen , Caenepeel Sean , Coxon Angela , Pili Roberto
Published: April 2023

Supplementary Figure S7 shows pathway alterations downstream of Tie2 and c-MET inhibition.
Supplementary Figure S5 from Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma
Authors: Elbanna May , Orillion Ashley R. , Damayanti Nur P. , Adelaiye-Ogala Remi , Shen Li , Miles Kiersten Marie , Chintala Sreenivasulu , Ciamporcero Eric , Ramakrishnan Swathi , Ku Sheng-yu , Rex Karen , Caenepeel Sean , Coxon Angela , Pili Roberto
Published: April 2023

Supplementary Figure S5 shows the effect of combination on E-Cadherin and Snail expression.
Supplementary Figures 1 -7 from The Novel Small-Molecule SR18662 Efficiently Inhibits the Growth of Colorectal Cancer In Vitro and In Vivo
Authors: Kim Julie , Wang Chao , de Sabando Ainara Ruiz , Cole Hannah L. , Huang Timothy J. , Yang Jie , Bannister Thomas D. , Yang Vincent W. , Bialkowska Agnieszka B.
Published: April 2023

Supplementary Figure S1. Synthesis steps of SR15006 and SR18662. Supplementary Figure S2. SR18662 changes cell cycle profiles of colorectal cancer cell lines. Supplementary Figure S3. SR18662 increases apoptosis of colorectal cancer cell lines. Supplementary Figures S4 - S6. SR18662 inhibits activity of MAPK, WNT/b-catenin signaling pathways and decreases the levels of cyclins. Supplementary Figure S7. The effect of SR18662 on the mice weight during xenograft studies.
Supplementary Figure S3 from Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma
Authors: Elbanna May , Orillion Ashley R. , Damayanti Nur P. , Adelaiye-Ogala Remi , Shen Li , Miles Kiersten Marie , Chintala Sreenivasulu , Ciamporcero Eric , Ramakrishnan Swathi , Ku Sheng-yu , Rex Karen , Caenepeel Sean , Coxon Angela , Pili Roberto
Published: April 2023

Supplementary Figure S3 shows additional tumor growth data
Supplementary Figure S10 from Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma
Authors: Elbanna May , Orillion Ashley R. , Damayanti Nur P. , Adelaiye-Ogala Remi , Shen Li , Miles Kiersten Marie , Chintala Sreenivasulu , Ciamporcero Eric , Ramakrishnan Swathi , Ku Sheng-yu , Rex Karen , Caenepeel Sean , Coxon Angela , Pili Roberto
Published: April 2023

Supplementary Figure S10 additional data on TIE2 and macrophage marker expression.
Supplementary Information from A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models
Authors: Ye Xiang S. , Fan Li , Van Horn Robert D. , Nakai Ryuichiro , Ohta Yoshihisa , Akinaga Shiro , Murakata Chikara , Yamashita Yoshinori , Yin Tinggui , Credille Kelly M. , Donoho Gregory P. , Merzoug Farhana F. , Li Heng , Aggarwal Amit , Blanchard Kerry , Westin Eric H.
Published: April 2023

Figure Legends to supplementary Figures 1-5
Supplementary Figure S1 from Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma
Authors: Elbanna May , Orillion Ashley R. , Damayanti Nur P. , Adelaiye-Ogala Remi , Shen Li , Miles Kiersten Marie , Chintala Sreenivasulu , Ciamporcero Eric , Ramakrishnan Swathi , Ku Sheng-yu , Rex Karen , Caenepeel Sean , Coxon Angela , Pili Roberto
Published: April 2023

Supplementary Figure S1 shows the chemical structure of compound 22.
Supplementary Figures 1-5 from A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models
Authors: Ye Xiang S. , Fan Li , Van Horn Robert D. , Nakai Ryuichiro , Ohta Yoshihisa , Akinaga Shiro , Murakata Chikara , Yamashita Yoshinori , Yin Tinggui , Credille Kelly M. , Donoho Gregory P. , Merzoug Farhana F. , Li Heng , Aggarwal Amit , Blanchard Kerry , Westin Eric H.
Published: April 2023

Supplementary Figure 1 (A-C). LY2523355 has potent and selective activity against microtubule-stimulated Eg5 ATPase activity but unlike antitubulins, has no effect on microtubule dynamics in vitro; supplementary Figure 2 (A-E). LY2523355 causes cell cycle arrest at mitosis with monopolar spindle and induces apoptosis; supplementary Figure 3 (A-D). Induction of apoptosis by LY2523355 requires sustained spindle assembly checkpoint (SAC)-mediated mitotic arrest; supplementary Figure 4 (A-D). Antitumor activity of LY2523355 in patient-derived xenograft (PDX) models is correlated with mitotic arrest of cancer cells; supplementary Figure 5 (A,B). Mitotic arrest and apotosis of p388 cells in ascities fluid after continuous infusion of LY2523355, demonstrating the threshold concentration effect.
Supplementary Tables from Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial with Predictive Molecular Correlates
Authors: Malhotra Usha , Mukherjee Sarbajit , Fountzilas Christos , Boland Patrick , Miller Austin , Patnaik Santosh , Attwood Kristopher , Yendamuri Sai , Adjei Araba , Kannisto Eric , Opyrchal Mateusz , Bushunow Peter , Loud Peter , Iyer Renuka , Khushalani Nikhil
Published: April 2023

Supplementary Table S1 is summarizing grade 3 or higher adverse events Supplementary Table S2 is listing the most common adverse events Supplementary Table S3 is summarizing the distribution of genotype and allele frequencies in patients Supplementary Table S4 is comparing between patients with a median overall survival of greater or less than 10 months, the historic median survival in this population Supplementary Table S5 is showing the median number of chemotherapy cycles by SNPs
Supplemental methods and tables from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Authors: Flynn Michael J. , Zammarchi Francesca , Tyrer Peter C. , Akarca Ayse U. , Janghra Narinder , Britten Charles E. , Havenith Carin E.G. , Levy Jean-Noel , Tiberghien Arnaud , Masterson Luke A. , Barry Conor , D'Hooge Francois , Marafioti Teresa , Parren Paul W.H.I. , Williams David G. , Howard Philip W. , van Berkel Patrick H. , Hartley John A.
Published: April 2023

Supplemental methods and tables
Supplementary Data from Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations
Authors: Park Pyoung Hwa , Yamamoto Tomomi M. , Li Hua , Alcivar Allen L. , Xia Bing , Wang Yifan , Bernhardy Andrea J. , Turner Kristen M. , Kossenkov Andrew V. , Watson Zachary L. , Behbakht Kian , Casadei Silvia , Swisher Elizabeth M. , Mischel Paul S. , Johnson Neil , Bitler Benjamin G.
Published: April 2023

Supplementary methods and figure legends. Figure S1 shows further characterization of Capan1 olaparib resistant cells and rucaparib resistant Capan1 cells. Figure S2 shows that drug efflux is unchanged in Capan1 olaparib resistant cells and truncated BRCA2 is overexpressed in rucaparib resistant Capan1 cells. Figure S3 shows that Capan1 olaparib resistant cells express truncated BRCA2 Figure S4 shows that Capan1 PARP inhibitor resistant cells form Rad51 and BRCA1 foci after irradiation. Figure S5 shows that BRCA2 knockdown sensitizes Capan1 olaparib resistant cells to olaparib. Figure S6 shows that BRCA2 peptide coverage and pinometostat-mediated reduction in H3K79Me in olaparib resistant Capan1 cells. Also DOT1L expression conveys poor prognosis in ovarian cancer and DOT1L knockdown reduced viability of an olaparib resistant ovarian cancer cell line.
Supplementary file from Leukocyte Differentiation by Histidine-Rich Glycoprotein/Stanniocalcin-2 Complex Regulates Murine Glioma Growth through Modulation of Antitumor Immunity
Authors: Roche Francis P. , Pietilä Ilkka , Kaito Hiroshi , Sjöström Elisabet O. , Sobotzki Nadine , Noguer Oriol , Skare Tor Persson , Essand Magnus , Wollscheid Bernd , Welsh Michael , Claesson-Welsh Lena
Published: April 2023

Supplementary Methods, Tables and Figures
Figure S8 from AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells
Authors: Verma Kshitij , Gupta Nehal , Zang Tianzhu , Wangtrakluldee Phumvadee , Srivastava Sanjay K. , Penning Trevor M. , Trippier Paul C.
Published: April 2023

Supplementary figure S8: Indomethacin exerts a weak synergistic drug effect in LNCaP1C3 cells and KV-37 does not induce cytotoxicity alone or in combination with ENZ in WPMY-1 cells.
Figure S7 from AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells
Authors: Verma Kshitij , Gupta Nehal , Zang Tianzhu , Wangtrakluldee Phumvadee , Srivastava Sanjay K. , Penning Trevor M. , Trippier Paul C.
Published: April 2023

Supplementary figure S7: Representative dot plots for Annexinv/FITC apoptosis assay.
Figure S6 from AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells
Authors: Verma Kshitij , Gupta Nehal , Zang Tianzhu , Wangtrakluldee Phumvadee , Srivastava Sanjay K. , Penning Trevor M. , Trippier Paul C.
Published: April 2023

Supplementary figure S6: Co-treatments of KV-37 with ENZ do not exert synergistic cytotoxic effects in LNCaP and 22Rv1 cells.
Figure S3 from AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells
Authors: Verma Kshitij , Gupta Nehal , Zang Tianzhu , Wangtrakluldee Phumvadee , Srivastava Sanjay K. , Penning Trevor M. , Trippier Paul C.
Published: April 2023

Supplementary figure S3: Metabolic instability of (A) Baccharin and (B) ester derivative KV-32 on incubation with mouse S9 fractions.
Figure S2 from AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells
Authors: Verma Kshitij , Gupta Nehal , Zang Tianzhu , Wangtrakluldee Phumvadee , Srivastava Sanjay K. , Penning Trevor M. , Trippier Paul C.
Published: April 2023

Supplementary figure S2. KV-37 inhibits conversion of [3H]Î"4-androstene-3,17-dione to testosterone in LNCaP-1C3 cells.
Figure S1 from AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells
Authors: Verma Kshitij , Gupta Nehal , Zang Tianzhu , Wangtrakluldee Phumvadee , Srivastava Sanjay K. , Penning Trevor M. , Trippier Paul C.
Published: April 2023

Supplementary figure S1. Competitive inhibition of NADPH dependent reduction of Î"4-androstene-3,17-dione mediated by AKR1C3 by KV-37.
Supplementary Video Legend from Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer
Authors: Fishel Melissa L. , Xia Hanyu , McGeown Jack , McIlwain David W. , Elbanna May , Craft Ariel A. , Kaimakliotis Hristos Z. , Sandusky George E. , Zhang Chi , Pili Roberto , Kelley Mark R. , Jerde Travis J.
Published: April 2023

Legend for supplementary videos.
Supplementary Video 3 from Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer
Authors: Fishel Melissa L. , Xia Hanyu , McGeown Jack , McIlwain David W. , Elbanna May , Craft Ariel A. , Kaimakliotis Hristos Z. , Sandusky George E. , Zhang Chi , Pili Roberto , Kelley Mark R. , Jerde Travis J.
Published: April 2023

Video of caspase 3 activity used to capture images used in quantification of caspase activation, indicating apoptosis induction. Representative video of UC3 cells treated with APX2009 as red indicator dye generated from Caspase 3. Duration of the video is the 72 hour duration of the experiment, as quantified and shown in Figure 2. Representative stills are shown in supplementary figure 3.
Supplementary Video 2 from Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer
Authors: Fishel Melissa L. , Xia Hanyu , McGeown Jack , McIlwain David W. , Elbanna May , Craft Ariel A. , Kaimakliotis Hristos Z. , Sandusky George E. , Zhang Chi , Pili Roberto , Kelley Mark R. , Jerde Travis J.
Published: April 2023

Video of caspase 3 activity used to capture images used in quantification of caspase activation, indicating apoptosis induction. Representative video of UC3 cells treated with DMSO control as red indicator dye generated from Caspase 3 activity is shown overlayed with brightfield image for each treatment. Duration of the video is the 72 hour duration of the experiment, as quantified and shown in Figure 2. Representative stills are shown in supplementary figure 3.
Fig. S4 from Photodynamic Therapy Using Indocyanine Green Loaded on Super Carbonate Apatite as Minimally Invasive Cancer Treatment
Authors: Tamai Koki , Mizushima Tsunekazu , Wu Xin , Inoue Akira , Ota Minori , Yokoyama Yuhki , Miyoshi Norikatsu , Haraguchi Naotsugu , Takahashi Hidekazu , Nishimura Junichi , Hata Taishi , Matsuda Chu , Doki Yuichiro , Mori Masaki , Yamamoto Hirofumi
Published: April 2023

Supplementary Figure S4. (A) Schematic presentation of generation of sCA incorporating ICG and glucose. (B) Plotted graph of encapsulation amount of ICG or glucose and amount of ICG added during complex formation. Glucose inclusion was almost constant irrespective of ICG addition. (C) sCA-ICG-glucose exhibited a significantly potent growth inhibition of HCT116 compared to sCA-ICG after NIR irradiation for 1, 3, 5 min.
Supplementary Table S1 from Androgen Receptor Signaling Reduces Radiosensitivity in Bladder Cancer
Authors: Ide Hiroki , Inoue Satoshi , Mizushima Taichi , Jiang Guiyang , Chuang Kuang-Hsiang , Oya Mototsugu , Miyamoto Hiroshi
Published: April 2023

Sequences of PCR primers.
Supplementary Data Figure S6 from CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death
Authors: Liu Xiaojun , Jiang Yingjun , Takata Kei-ichi , Nowak Billie , Liu Chaomei , Wood Richard D. , Hittelman Walter N. , Plunkett William
Published: April 2023

Supplemental Figure S6 shows time-lapse video microscopy of lung cancer H460 cells after washout of CNDAC.
Supplementary Data Figure S5 from CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death
Authors: Liu Xiaojun , Jiang Yingjun , Takata Kei-ichi , Nowak Billie , Liu Chaomei , Wood Richard D. , Hittelman Walter N. , Plunkett William
Published: April 2023

Supplemental Figure S5 shows timelines of CNDAC treatment and washout, and the criteria for cell tracking in live cell imaging of AA8 (A) and H460 (B) cell lines.
Supplementary Data Figure S3 from CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death
Authors: Liu Xiaojun , Jiang Yingjun , Takata Kei-ichi , Nowak Billie , Liu Chaomei , Wood Richard D. , Hittelman Walter N. , Plunkett William
Published: April 2023

Supplemental Figure S3 shows proliferation rate of mouse and human cell lines proficient and deficient in DNA polymerase Pol theta in culture.
Supplementary Data Figure S2 from CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death
Authors: Liu Xiaojun , Jiang Yingjun , Takata Kei-ichi , Nowak Billie , Liu Chaomei , Wood Richard D. , Hittelman Walter N. , Plunkett William
Published: April 2023

Supplemental Figure S2 shows comet assays of UV41 (Xpf mutant) and AA8 (WT) cells in response to CNDAC treatment.
Figure S5 from Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma In Vitro and Patient-Derived Xenografts In Vivo
Authors: Song Mengqiu , Liu Xuejiao , Liu Kangdong , Zhao Ran , Huang Hai , Shi Yuanyuan , Zhang Man , Zhou Silei , Xie Hua , Chen Hanyong , Li Yin , Zheng Yan , Wu Qiong , Liu Fangfang , Li Enmin , Bode Ann M. , Dong Zigang , Lee Mee-Hyun
Published: April 2023

The bioactivity of 5-FU or cisplatin alone against ESCC cells. (A) 5-FU or cisplatin alone decreased cell proliferation in a concentration- dependent manner in KYSE450 and KYSE410 ESCC cells. Data are shown as means {plus minus} S.D. of values from triplicate samples. (B) Combination index of oridonin with 5-FU or cisplatin.
Supplementary Data Figure S1 from CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death
Authors: Liu Xiaojun , Jiang Yingjun , Takata Kei-ichi , Nowak Billie , Liu Chaomei , Wood Richard D. , Hittelman Walter N. , Plunkett William
Published: April 2023

Supplemental Figure S1 shows cell cycle progression of CHO cell lines proficient and deficient in XPF after CNDAC treatment.
Supplementary Table III from Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097
Authors: Weisberg Ellen , Halilovic Ensar , Cooke Vesselina G. , Nonami Atsushi , Ren Tao , Sanda Takaomi , Simkin Irene , Yuan Jing , Antonakos Brandon , Barys Louise , Ito Moriko , Stone Richard , Galinsky Ilene , Cowens Kristen , Nelson Erik , Sattler Martin , Jeay Sebastien , Wuerthner Jens U. , McDonough Sean M. , Wiesmann Marion , Griffin James D.
Published: April 2023

Supplementary Table III: AML patient samples tested with HDM2 inhibitor, CGM097: IC50 values for CGM097.
Figure S1 from Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma In Vitro and Patient-Derived Xenografts In Vivo
Authors: Song Mengqiu , Liu Xuejiao , Liu Kangdong , Zhao Ran , Huang Hai , Shi Yuanyuan , Zhang Man , Zhou Silei , Xie Hua , Chen Hanyong , Li Yin , Zheng Yan , Wu Qiong , Liu Fangfang , Li Enmin , Bode Ann M. , Dong Zigang , Lee Mee-Hyun
Published: April 2023

The activity of oridonin against Akt and Akt-related kinases. (A) The effect of increasing concentrations of oridonin against EGFR activation. (B) The effect of increasing concentrations of oridonin against c-Src. (C) The effect of increasing concentrations of oridonin against FGFR2. (D) Kinase profiling data of oridoin activity against Akt-related kinases. (E) Lineweaver-Burke plot of oridonin effect against Akt1 and Akt2 kinase activity.
Supplemental figure 2 from Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers
Authors: Li Chunrong , Huang Shyhmin , Armstrong Eric A. , Francis David M. , Werner Lauryn R. , Sliwkowski Mark X. , van der Kogel Albert , Harari Paul M.
Published: April 2023

MEHD7945A was more effective than anti-EGFR or anti-HER3 antibody in inhibiting cell signaling, cell proliferation and clonogenity.
Supplementary Figure S1 from MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
Authors: Merlino Giuseppe , Fiascarelli Alessio , Bigioni Mario , Bressan Alessandro , Carrisi Corrado , Bellarosa Daniela , Salerno Massimiliano , Bugianesi Rossana , Manno Rosanna , Bernadó Morales Cristina , Arribas Joaquin , Bisht Arnima , Kaplan Angelo , Boyd Robert , Do Uyen T. , Swaminathan Sudha , Attanasio Nickolas , Lou San Lin , Dusek Rachel L. , Ackroyd James E. , Pham Phuoc Huy , Awdew Rahel , Aud Dee , Trang Michael , Lynch Carmel M. , Terrett Jonathan , Wilson Keith E. , Rohlff Christian , Manzini Stefano , Pellacani Andrea , Binaschi Monica
Published: April 2023

Supplementary Figure S1. Representative images of IHC staining for CD205 in different human and cynomolgus tissues, obtained with 2 μg/ml of MEN1309/OBT076 at 20X and 10X magnification. 1) Human donor spleen; moderate to strong membranous/granular cytoplasmic staining of several mononuclear cells present in the white pulp of the spleen (circle); 2) Cynomolgus donor spleen; the staining intensity and distribution pattern was very similar to that described in human samples; 3) Human donor lymph node; a moderate to marked membranous/cytoplasmic staining of mononuclear cells in the cortex, para-cortex and germinal centers of lymphoid follicles was observed; 4) Cynomolgus donor lymph node; positive mononuclear cells presented a moderate to strong membranous/granular cytoplasmic staining; 5) Human donor breast; a concentration-dependent cytoplasmic staining of epithelial cells in glandular alveoli (rectangle) and ducts (circle); 6) Cynomolgus donor breast; the staining was weaker in intensity when compared to human donors, but the pattern was comparable; 7) Human donor colon; membranous/cytoplasmic signal of a variable number of mononuclear cells was observed in the lamina propria and GALT (circle). Minimal to slight cytoplasmic staining of the superficial mucosal epithelium (rectangle); 8) Cynomolgus donor colon; a variable number of mononuclear cells located in lamina propria and GALT (circle) are positive with membranous/cytoplasmic signal; 9) Human donor ureter; a minimal but concentration-dependent staining was observed in mucosal epithelium (rectangle). Rare mononuclear cells with positive signal in lamina propria (circles); 10) Cynomolgus donor ureter; occasional mononuclear cells with membranous/granular cytoplasmic staining was observed in the lamina propria; 11) Human donor cervix; a concentration-dependent cytoplasmic staining of cervical gland epithelium was observed (circle). Cytoplasmic staining of the basal cell layer of mucosal epithelium was also observed (rectangle); 12) Cynomolgus donor cervix; positive mononuclear cells with a membranous/granular cytoplasmic staining were present in the mucosa-associated lymphoid nodules (circle).
Supplemental figure 1 from Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers
Authors: Li Chunrong , Huang Shyhmin , Armstrong Eric A. , Francis David M. , Werner Lauryn R. , Sliwkowski Mark X. , van der Kogel Albert , Harari Paul M.
Published: April 2023

MEHD7945A can inhibit activation of EGFR and HER3 in a dose-dependent manner.
Supplementary Table S2 from MiRNA-203 Reduces Nasopharyngeal Carcinoma Radioresistance by Targeting IL8/AKT Signaling
Authors: Qu Jia-Quan , Yi Hong-Mei , Ye Xu , Zhu Jin-Feng , Yi Hong , Li Li-Na , Xiao Ta , Yuan Li , Li Jiao-Yang , Wang Yuan-Yuan , Feng Juan , He Qiu-Yan , Lu Shan-Shan , Xiao Zhi-Qiang
Published: April 2023

QRT-PCR primers for amplification of miR-203 and IL-8 synthesized by Ribobio
Figure S1 from A Novel Salicylanilide Derivative Induces Autophagy Cell Death in Castration-Resistant Prostate Cancer via ER Stress-Activated PERK Signaling Pathway
Authors: Hsieh Chia-Ling , Huang Hsu-Shan , Chen Kuan-Chou , Saka Teigi , Chiang Chih-Ying , Chung Leland W.K. , Sung Shian-Ying
Published: April 2023

Effect of LCC03 on cell cycle of prostate cancer cells.
Supplementary Figure S2 from MiRNA-203 Reduces Nasopharyngeal Carcinoma Radioresistance by Targeting IL8/AKT Signaling
Authors: Qu Jia-Quan , Yi Hong-Mei , Ye Xu , Zhu Jin-Feng , Yi Hong , Li Li-Na , Xiao Ta , Yuan Li , Li Jiao-Yang , Wang Yuan-Yuan , Feng Juan , He Qiu-Yan , Lu Shan-Shan , Xiao Zhi-Qiang
Published: April 2023

The cutoff value of miR-203 that could be used to differentiate between the radioresistant and radiosensitive NPC patients was determined by receiver-operating characteristic (ROC) analysis (P<0.001; AUC, 0.94; cutoff value, 1.05).
Supplementary Figure S1 from MiRNA-203 Reduces Nasopharyngeal Carcinoma Radioresistance by Targeting IL8/AKT Signaling
Authors: Qu Jia-Quan , Yi Hong-Mei , Ye Xu , Zhu Jin-Feng , Yi Hong , Li Li-Na , Xiao Ta , Yuan Li , Li Jiao-Yang , Wang Yuan-Yuan , Feng Juan , He Qiu-Yan , Lu Shan-Shan , Xiao Zhi-Qiang
Published: April 2023

The targets for human IL-8 shRNA vector and their efficacy of IL-8 knockdown.(top) the targets for human IL-8 shRNA; (bottom) a representative result of Western blotting shows that the expression levels of IL-8 in the CNE2-IR cells transiently transfected with psi-LVRU6GP-IL-8 shRNA vector expressing IL-8 shRNA1, shRNA2, shRNA3 or shRNA4. Knockdown efficacy of IL-8 shRNA1 and shRNA2 was better than that of the other two IL-8 shRNAs, thus IL-8 shRNA1 and shRNA2 vectors were selected for establishing stably transfected CNE2-IR cell lines.
Supplementary Table S2 from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3–Knockin Mice
Authors: Burova Elena , Hermann Aynur , Dai Jie , Ullman Erica , Halasz Gabor , Potocky Terra , Hong Seongwon , Liu Matt , Allbritton Omaira , Woodruff Amy , Pei Jerry , Rafique Ashique , Poueymirou William , Martin Joel , MacDonald Douglas , Olson William C. , Murphy Andrew , Ioffe Ella , Thurston Gavin , Mohrs Markus
Published: April 2023

Supplementary Table S2 shows PK data for REGN3767 in monkeys
Supplementary Materials and Methods from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3–Knockin Mice
Authors: Burova Elena , Hermann Aynur , Dai Jie , Ullman Erica , Halasz Gabor , Potocky Terra , Hong Seongwon , Liu Matt , Allbritton Omaira , Woodruff Amy , Pei Jerry , Rafique Ashique , Poueymirou William , Martin Joel , MacDonald Douglas , Olson William C. , Murphy Andrew , Ioffe Ella , Thurston Gavin , Mohrs Markus
Published: April 2023

Supplementary materials and methods
Supplementary Figure S4 from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3–Knockin Mice
Authors: Burova Elena , Hermann Aynur , Dai Jie , Ullman Erica , Halasz Gabor , Potocky Terra , Hong Seongwon , Liu Matt , Allbritton Omaira , Woodruff Amy , Pei Jerry , Rafique Ashique , Poueymirou William , Martin Joel , MacDonald Douglas , Olson William C. , Murphy Andrew , Ioffe Ella , Thurston Gavin , Mohrs Markus
Published: April 2023

Supplementary Figure S4 shows activity of REGN3767 in an engineered assay
Supplementary Figure S3 from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3–Knockin Mice
Authors: Burova Elena , Hermann Aynur , Dai Jie , Ullman Erica , Halasz Gabor , Potocky Terra , Hong Seongwon , Liu Matt , Allbritton Omaira , Woodruff Amy , Pei Jerry , Rafique Ashique , Poueymirou William , Martin Joel , MacDonald Douglas , Olson William C. , Murphy Andrew , Ioffe Ella , Thurston Gavin , Mohrs Markus
Published: April 2023

Supplementary Figure S3 shows blocking activity of anti-MHC class II antibody in in vitro assay
Supplementary Figure S1 from Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3–Knockin Mice
Authors: Burova Elena , Hermann Aynur , Dai Jie , Ullman Erica , Halasz Gabor , Potocky Terra , Hong Seongwon , Liu Matt , Allbritton Omaira , Woodruff Amy , Pei Jerry , Rafique Ashique , Poueymirou William , Martin Joel , MacDonald Douglas , Olson William C. , Murphy Andrew , Ioffe Ella , Thurston Gavin , Mohrs Markus
Published: April 2023

Supplementary Figure S1 shows the amino acid sequences of the heavy and light chains of REGN3767
Supplementary Material from Selective PRMT5 Inhibitors Suppress Human CD8+ T Cells by Upregulation of p53 and Impairment of the AKT Pathway Similar to the Tumor Metabolite MTA
Authors: Strobl Carolin Dorothea , Schaffer Stefanie , Haug Tabea , Völkl Simon , Peter Katrin , Singer Katrin , Böttcher Martin , Mougiakakos Dimitrios , Mackensen Andreas , Aigner Michael
Published: April 2023

Supplementary table 1 - Antibodies used for flow cytometry analysis; Supplemenary table 2 - Antibodies used for Western blot analysis; Supplemenary table 3 - Primer and PCR conditions used for MDM4 alternative splicing PCR
Supplementary Figures from Selective PRMT5 Inhibitors Suppress Human CD8+ T Cells by Upregulation of p53 and Impairment of the AKT Pathway Similar to the Tumor Metabolite MTA
Authors: Strobl Carolin Dorothea , Schaffer Stefanie , Haug Tabea , Völkl Simon , Peter Katrin , Singer Katrin , Böttcher Martin , Mougiakakos Dimitrios , Mackensen Andreas , Aigner Michael
Published: April 2023

Supplementary Figure S1 - Evaluation of the synergistic effect of the PRMT5-inhibiting molecules MTA and EPZ015666; Supplementary Figure S2 - PRMT5 inhibition reduces T-cell proliferation, viability and functionality; Supplementary Figure S3 - PRMT5 inhibition impairs T-cell differentiation in a dose-dependent manner; Supplementary Figure S4 - PRMT5 inhibition impairs differentiation of antigen-specific cytotoxic T-cells; Supplementary Figure S5 - Inhibition of PRMT5 impairs fatty acid utilization after T-cell stimulation; Supplementary Figure S6 - Impact of IL-7 on PRMT5 inhibition-mediated T-cell suppression; Supplementary Figure S7 - Impact of IL-7 on PRMT5 inhibition-mediated suppression of T-cell metabolism; Supplementary Figure S8 - Possible links between PRMT5 inhibition and AKT signaling
Supplementary Figure 5 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment
Authors: Rosas-Plaza Ximena , de Vries Gerda , Meersma Gert Jan , Suurmeijer Albert J.H. , Gietema Jourik A. , van Vugt Marcel A.T.M. , de Jong Steven
Published: April 2023

Autophagy induction and the effect on apoptosis in cisplatin resistant TC cells
Supplementary Figure 4 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment
Authors: Rosas-Plaza Ximena , de Vries Gerda , Meersma Gert Jan , Suurmeijer Albert J.H. , Gietema Jourik A. , van Vugt Marcel A.T.M. , de Jong Steven
Published: April 2023

mTORC1/2 downstream pathway evaluation in Tera cells
Table S1 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
Authors: Irie Hiroki , Ito Kimihiro , Fujioka Yayoi , Oguchi Kei , Fujioka Akio , Hashimoto Akihiro , Ohsawa Hirokazu , Tanaka Kenji , Funabashi Kaoru , Araki Hikari , Kawai Yuichi , Shimamura Tadashi , Wadhwa Renu , Ohkubo Shuichi , Matsuo Kenichi
Published: April 2023

IC50 values of TAS0728 against kinases
Table S1 from Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway
Authors: Zhou Sheng , Xu Huanji , Tang Qiulin , Xia Hongwei , Bi Feng
Published: April 2023

Correlation between HMGCS1 expression and clinicopathological features of patients tissues specimens
Figure S1 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
Authors: Irie Hiroki , Ito Kimihiro , Fujioka Yayoi , Oguchi Kei , Fujioka Akio , Hashimoto Akihiro , Ohsawa Hirokazu , Tanaka Kenji , Funabashi Kaoru , Araki Hikari , Kawai Yuichi , Shimamura Tadashi , Wadhwa Renu , Ohkubo Shuichi , Matsuo Kenichi
Published: April 2023

Synthetic procedures
Figure S4 from Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway
Authors: Zhou Sheng , Xu Huanji , Tang Qiulin , Xia Hongwei , Bi Feng
Published: April 2023

The synergistic effect of trametinib and dipyridamole in CRC cells.
Supplementary Table 2 from Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
Authors: Mastri Michalis , Lee Christina R. , Tracz Amanda , Kerbel Robert S. , Dolan Melissa , Shi Yuhao , Ebos John M.L.
Published: April 2023

List of treatment-induced secretory gene expression changes for RTKIs and Abs (from Fig 2).
Figure S3 from Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway
Authors: Zhou Sheng , Xu Huanji , Tang Qiulin , Xia Hongwei , Bi Feng
Published: April 2023

Suppression of HMGCS1 completely reduces the EGF-induced cell proliferation and survival of colon cancer cells.
Figure S1 from Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway
Authors: Zhou Sheng , Xu Huanji , Tang Qiulin , Xia Hongwei , Bi Feng
Published: April 2023

HMGCS1 regulates the migration of colon cancer cells.
Supplementary Figure S1 from Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo
Authors: Lopez Salvatore , Cocco Emiliano , Black Jonathan , Bellone Stefania , Bonazzoli Elena , Predolini Federica , Ferrari Francesca , Schwab Carlton L. , English Diana P. , Ratner Elena , Silasi Dan-Arin , Azodi Masoud , Schwartz Peter E. , Terranova Corrado , Angioli Roberto , Santin Alessandro D.
Published: April 2023

Graph showing IC50 values for USPC-ARK-1 cell line after 72 hrs exposure to increasing concentration of neratinib.
Supplementary Methods, Tables, and Figures from Antitumor Activity of the IGF-1/IGF-2–Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models
Authors: Weyer-Czernilofsky Ulrike , Hofmann Marco H. , Friedbichler Katrin , Baumgartinger Rosa , Adam Paul J. , Solca Flavio , Kraut Norbert , Nguyen Holly M. , Corey Eva , Liu Gang , Sprenger Cynthia C. , Plymate Stephen R. , Bogenrieder Thomas
Published: April 2023

Supplementary Methods. Supplementary Table S1 shows the dates of mycoplasma testing and STR analysis for each cell line; Supplementary Table S2 shows the primary antibodies used for Western blot or Simple Western{trade mark, serif} analysis, and the TaqMan primer and probe sets used for real-time qPCR; Supplementary Table S3 shows the GSEA results of all C2-canonical pathways with false discovery rate < 0.05; Supplementary Fig. S1 shows protein expression of AR, IGF-1R, and PTEN, and the effect of ENZA and XENT, alone or in combination, on IGF-1R and AKT phosphorylation status in prostate cancer cells; Supplementary Fig. S2 shows analysis of PTEN knockdown by qPCR and Western blot; Supplementary Fig. S3 shows the effect of XENT and ENZA, alone or in combination, on transcript and protein levels of AR-regulated and AR-V7 target genes in VCaP cells; Supplementary Fig. S4 shows the effect of XENT and ENZA, alone or in combination, on caspase 3/7 activity and on total protein levels of apoptotic regulators; Supplementary Fig. S5 shows AR-FL and AR-V7 mRNA and protein expression in LuCaP 96CR PDX; Supplementary Fig. S6 shows the paired end, unstranded RNA-Seq profile matching to the PTEN locus in LuCaP 96CR.
Supplemental Movie 5 from The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-Catenin
Authors: Shukla Samriddhi , Milewski David , Pradhan Arun , Rama Nihar , Rice Kathryn , Le Tien , Flick Matthew J. , Vaz Sara , Zhao Xueheng , Setchell Kenneth D. , Logarinho Elsa , Kalinichenko Vladimir V. , Kalin Tanya V.
Published: April 2023

Supplemental movie 5 shows live imaging to measure the cell cycle and mitotic duration in Vehicle-treated MyC-CaP cells.
Supplemental Movie 4 from The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-Catenin
Authors: Shukla Samriddhi , Milewski David , Pradhan Arun , Rama Nihar , Rice Kathryn , Le Tien , Flick Matthew J. , Vaz Sara , Zhao Xueheng , Setchell Kenneth D. , Logarinho Elsa , Kalinichenko Vladimir V. , Kalin Tanya V.
Published: April 2023

Supplemental movie 4 shows live imaging to measure the cell cycle and mitotic duration in RCM-1-treated B16-F10 cells.
Supplemental Movie 2 from The FOXM1 Inhibitor RCM-1 Decreases Carcinogenesis and Nuclear β-Catenin
Authors: Shukla Samriddhi , Milewski David , Pradhan Arun , Rama Nihar , Rice Kathryn , Le Tien , Flick Matthew J. , Vaz Sara , Zhao Xueheng , Setchell Kenneth D. , Logarinho Elsa , Kalinichenko Vladimir V. , Kalin Tanya V.
Published: April 2023

Supplemental movie 2 shows live imaging to measure the cell cycle and mitotic duration in RCM-1-treated Rd76-9 cells.
Supplementary Materials and Methods from A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
Authors: Sasikumar Pottayil G. , Ramachandra Raghuveer K. , Adurthi Srinivas , Dhudashiya Amit A. , Vadlamani Sureshkumar , Vemula Koteswararao , Vunnum Sriharibabu , Satyam Leena K. , Samiulla Dodderi S. , Subbarao Krishnaprasad , Nair Rashmi , Shrimali Rajeev , Gowda Nagaraj , Ramachandra Murali
Published: April 2023

Supplementary methods
Supplementary Figure 4 NP-12 increased the levels of IFN-γ in the Cytomegalovirus (CMV) antigen recall assay from A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
Authors: Sasikumar Pottayil G. , Ramachandra Raghuveer K. , Adurthi Srinivas , Dhudashiya Amit A. , Vadlamani Sureshkumar , Vemula Koteswararao , Vunnum Sriharibabu , Satyam Leena K. , Samiulla Dodderi S. , Subbarao Krishnaprasad , Nair Rashmi , Shrimali Rajeev , Gowda Nagaraj , Ramachandra Murali
Published: April 2023

Supplementary Figure 4 NP-12 increased the levels of IFN-γ in the Cytomegalovirus (CMV) antigen recall assay
Supplementary Figure 1 NP-12 labeled with FITC shows higher binding to CHOK1 cells overexpressing PD-L1 as compared to WT CHOK1 cells from A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy
Authors: Sasikumar Pottayil G. , Ramachandra Raghuveer K. , Adurthi Srinivas , Dhudashiya Amit A. , Vadlamani Sureshkumar , Vemula Koteswararao , Vunnum Sriharibabu , Satyam Leena K. , Samiulla Dodderi S. , Subbarao Krishnaprasad , Nair Rashmi , Shrimali Rajeev , Gowda Nagaraj , Ramachandra Murali
Published: April 2023

Supplementary Figure 1 NP-12 labeled with FITC shows higher binding to CHOK1 cells overexpressing PD-L1 as compared to WT CHOK1 cells
Supplementary Note from Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers
Authors: Stewart Adam , Coker Elizabeth A. , Pölsterl Sebastian , Georgiou Alexandros , Minchom Anna R. , Carreira Suzanne , Cunningham David , O'Brien Mary ER. , Raynaud Florence I. , de Bono Johann S. , Al-Lazikani Bissan , Banerji Udai
Published: April 2023

Supplementary Note
Supplementary Materials and Methods, Supplementary Table 2, and Supplementary Figures 1 and 2 from Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5
Authors: Le Gall Marianne , Crépin Ronan , Neiveyans Madeline , Auclair Christian , Fan Yongfeng , Zhou Yu , Marks James D. , Pèlegrin André , Poul Marie-Alix
Published: April 2023

Materials and methods describing the production of scFv-Fc in HEK-T cells and KIT domains and scFv display on yeast. Table S2: Primers for PCR amplification of KIT and cloning into pYD vector by Gap repair. Figure S1: Selection and initial characterization of a panel of anti-KIT scFv. Figure S2: Anti-KIT D5 epitope characterization using yeast display.
Supplementary Figures 3 and 4 from Neutralization of KIT Oncogenic Signaling in Leukemia with Antibodies Targeting KIT Membrane Proximal Domain 5
Authors: Le Gall Marianne , Crépin Ronan , Neiveyans Madeline , Auclair Christian , Fan Yongfeng , Zhou Yu , Marks James D. , Pèlegrin André , Poul Marie-Alix
Published: April 2023

Figure S3: Characterization of UT-7/Epo, HMC1.1 and HMC1.2 cell lines. Figure S4: 2D1 and 3G1-Fc do not compete with 104D2 mAb binding to KIT.
Supplementary Data from Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers
Authors: Stewart Adam , Coker Elizabeth A. , Pölsterl Sebastian , Georgiou Alexandros , Minchom Anna R. , Carreira Suzanne , Cunningham David , O'Brien Mary ER. , Raynaud Florence I. , de Bono Johann S. , Al-Lazikani Bissan , Banerji Udai
Published: April 2023

Cell lines, culture medium, drug concentrations, cell culture, methods for producing Figure 1
Supplementary Methods from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
Authors: Wengner Antje M. , Siemeister Gerhard , Lücking Ulrich , Lefranc Julien , Wortmann Lars , Lienau Philip , Bader Benjamin , Bömer Ulf , Moosmayer Dieter , Eberspächer Uwe , Golfier Sven , Schatz Christoph A. , Baumgart Simon J. , Haendler Bernard , Lejeune Pascale , Schlicker Andreas , von Nussbaum Franz , Brands Michael , Ziegelbauer Karl , Mumberg Dominik
Published: April 2023

Detailed method descriptions
Supplementary Figures from The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
Authors: Wengner Antje M. , Siemeister Gerhard , Lücking Ulrich , Lefranc Julien , Wortmann Lars , Lienau Philip , Bader Benjamin , Bömer Ulf , Moosmayer Dieter , Eberspächer Uwe , Golfier Sven , Schatz Christoph A. , Baumgart Simon J. , Haendler Bernard , Lejeune Pascale , Schlicker Andreas , von Nussbaum Franz , Brands Michael , Ziegelbauer Karl , Mumberg Dominik
Published: April 2023

Figures S1-S4
Supplementary Materials and Methods from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
Authors: Manara Maria Cristina , Valente Sergio , Cristalli Camilla , Nicoletti Giordano , Landuzzi Lorena , Zwergel Clemens , Mazzone Roberta , Stazi Giulia , Arimondo Paola B. , Pasello Michela , Guerzoni Clara , Picci Piero , Nanni Patrizia , Lollini Pier-Luigi , Mai Antonello , Scotlandi Katia
Published: April 2023

Additional materials and methods
Supplementary Materials and Methods and Supplementary Tables S3, S4, S6, S8, and S9 from Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing
Authors: Das Sunetra , Idate Rupa , Cronise Kathryn E. , Gustafson Daniel L. , Duval Dawn L.
Published: April 2023

Section 1: Supplementary Materials and Methods Section 2: Supplementary Tables Supplementary Table S3. Tools and databases used in this study. Supplementary Table S4. Primers used for validating variants. Supplementary Table S6. Putative driver gene mutations. Supplementary Table S8. Mutated MAPK genes mapped to KEGG pathway (cfa:04010). Supplementary Table S9. Mutated PI3K-AKT genes mapped to KEGG pathway (cfa:04151).